Today: November 19, 2017, 12:30 am
  
Science

KinderPharm LLC Acquires Clinical Pharmacology and Pharmacometric Research and Development Company

KinderPharm LLC., announced that it has acquired PKPD Bioscience, Inc., a clinical pharmacology and pharmacometric research and development company. The purchase will strengthen the capabilities of KinderPharm LLC to provide pediatric PK/PD modeling and simulation as well as Pop PK and sparse sampling.
KinderPharm LLC Acquires Clinical Pharmacology and Pharmacometric Research and Development Company
PR-Inside.com: 2015-08-31 18:08:53
KinderPharm LLC., announced that it has acquired PKPD Bioscience, Inc., a clinical pharmacology and pharmacometric research and development company. The purchase will strengthen the capabilities of KinderPharm LLC to provide pediatric PK/PD modeling and simulation as well as Pop PK and sparse sampling. The acquisition will better serve the needs of KinderPharm’s customers by meeting the FDA “Critical Path Initiative” of implementing PK/PD modeling and simulation into all pediatric trials by 2020.


Pediatric PK/PD modeling and simulation is a rapidly evolving science. Application of these strategies can have an enormous impact on the design of pediatric studies, providing insight and guidance on the rational selection of pediatric doses and dose regimens.

PopPK analysis can be used to estimate pharmacokinetic parameters from very sparse datasets (e.g. one or two samples) collected at random sampling times through the disposition of the drug. This is a particularly valuable tool in pediatric drug development as it can be used to analyze PK data in children with a minimal number of blood draws. In addition to PopPK strategies, PKPD Bioscience scientists also make use of computer-based algorithms to design optimized blood-draw schedules to minimize the number of samples that need to be taken from children to obtain PK data.

“Our acquisition of PKPD Bioscience complements our overall pediatric drug development offering so we can provide minimal exposure to clinical testing to children, advance proof of concept through modeling and simulation techniques and provide cost savings to Pharmaceutical and Biotech partners through expedited drug development processes. This investment represents an important strategic opportunity to offer a full service model enabling us to efficiently and cost-effectively advance pediatric products through all the required stages of pre-clinical and clinical development.” said Lynda Graham, CFO of KinderPharm LLC. “The acquisition also adds to the talents and experience of our people, to provide us with a unique set of expertise, skill and insight to tackle the most challenging of development issues.”

About KinderPharm and PKPD Bioscience

KinderPharm, LLC, based in Exton, PA, is an expert pediatric co-development partner, focusing exclusively on pediatric drug development. Our out-sourced “Pediatric Center of Excellence” model is a unique resource of pediatricians, pharmacometricians, regulatory, drug safety and formulation scientists that develop pediatric drugs through all stages of development. Our seasoned teams bring expertise and insight to help effectively navigate the complex pediatric regulatory environments in the US and Europe. We are dedicated to one single goal namely “Bringing better medicines to children”. To learn more information about KinderPharm visit www.kinderpharm.com

PKPD Bioscience is a division of KinderPharm. LLC, providing advanced pharmacokinetic data analysis services to the pharmaceutical and biotechnology industry. PKPD utilizes cutting edge, computer-based drug modeling and clinical trial simulation techniques to develop optimized dosing regimens during pre-clinical and clinical drug development. Drug modeling and simulation has been recognized by the FDA as a “critical path” enabling technology that assists pharmaceutical and biotechnology companies in the selection of safe and effective dosing regimens for late stage clinical development and registration. PKPD Bioscience aims to be the primary provider of innovative and rational approaches to pediatric drug development, assisting companies to more rapidly and safely advance new medicines for children to the marketplace for an earlier return on investment. To learn more about PKPD Bioscience, visit www.pkpdinc.com

___

For further information, please contact:

 Martin Graham, PhD, Chief Executive Officer, (610) 458-1052

 Janet Welsko, Chief Operating Officer, (610) 458-1052

 Lynda Graham, MBA, Chief Financial Officer, (610) 458-1052

For media inquiries, please contact:

 Kristin Liezenga, Business Development Executive, (610) 458-1502

Press Information
KinderPharm LLC
717 Constitution Drive

Suite 104

Exton, PA 19341

Lynda Graham
CFO
610-458-1052
email
www.kinderpharm.com


# 630 Words
Related Articles
 
More From Science
MyScienceWork announces collaboration with The French Institute [..]
Virginie Simon, CEO of MyScienceWork said: “We are very proud to work with the international renowned institution INED and [..]
The game algorithm that could improve materials [..]
Tsukuba, Japan, Aug 23, 2017 - (ACN Newswire) - Designing advanced materials is a complex process, with many potential combinations [..]
SpectralWorks Limited and Mestrelab Research SL announce [..]
The software companies SpectralWorks Ltd (SpectralWorks) and Mestrelab Research SL (Mestrelab) announced today that they have [..]
Mangroves vital for environmental decontamination
Selangor, Malaysia, Aug 5, 2017 - (ACN Newswire) - Grey mangrove trees, Avicennia marina, filter heavy metals out of the [..]
Who learns foreign language better - introverts [..]
Extravert Chinese students learning English as a second language are likely to perform better in speaking and reading, but less [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.